Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 18,574 shares at $518.54 ($9.6M) on 2020-04-14, disclosed to the SEC on 2020-04-15.
Open-market sale of $9.6M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $511.56 | 7,582 | $3.9M | 40.4% |
| 2 | $517.99 | 2 | $1K | 0.0% |
| 3 | $518.54 | 267 | $138K | 1.4% |
| 4 | $518.54 | 267 | $138K | 1.4% |
| 5 | $519.85 | 422 | $219K | 2.3% |
| 6 | $519.85 | 422 |
| $219K |
| 2.3% |
| 7 | $520.43 | 2,096 | $1.1M | 11.4% |
| 8 | $520.43 | 2,096 | $1.1M | 11.4% |
| 9 | $521.32 | 1,595 | $832K | 8.7% |
| 10 | $521.32 | 1,595 | $832K | 8.7% |
| 11 | $522.37 | 758 | $396K | 4.1% |
| 12 | $522.37 | 758 | $396K | 4.1% |
| 13 | $524.26 | 357 | $187K | 1.9% |
| 14 | $524.26 | 357 | $187K | 1.9% |
| Total | $517.19 avg | 18,574 | $9.6M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |